Clicky

Friday, November 20, 2026
All public companies · Official EDGAR

RTSNRetension Pharmaceuticals, Inc.

Nasdaq · CIK 0002002988
Filer categoryNon-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Entity typeoperating
SIC2834 Pharmaceutical Preparations
FY end1231
XBRL facts77

Identity from submissions API

NameRetension Pharmaceuticals, Inc.
CIK0002002988
TickersRTSN
ExchangesNasdaq
Entity typeoperating
CategoryNon-accelerated filer<br>Smaller reporting company<br>Emerging growth company
SIC2834 Pharmaceutical Preparations
EIN932592788
LEI—
Fiscal year end1231
State of incorporationDE DE
Phone(703) 624-2024
Website—
Investor website—
Owner org03 Life Sciences
Flags—
Description—
Insider transactions (issuer)1
Insider transactions (owner)0

Former names

  • None listed.
Business address
C/O REDUX THERAPEUTICS, LLC
902 TURKEY RUN ROAD
MCLEAN
VA
22101
VA
Mailing address
C/O REDUX THERAPEUTICS, LLC
902 TURKEY RUN ROAD
MCLEAN
VA
22101
VA

EDGAR has no company-logo API. Website field is shown when the filer provided one.

Financialist coverage

SEC filings

47 filing rows loaded from submissions recent.

FiledFormDocumentItemsAccessionFile no.FilmActSizeXBRLiXBRL
2026-11-18 10-Q 10-Q 0001104659-26-129357 001-43503 261568092 34 5725811 1 1
2026-11-18 8-K 8-K 2.02,9.01 0001104659-26-129354 001-43503 261568084 34 305251 1 1
2026-11-04 4 xslF345X06/ownership.xml 0001213900-26-115968 5796
2026-11-04 3 xslF345X06/ownership.xml 0001213900-26-115961 8225
2026-10-23 8-K CURRENT REPORT 5.02,9.01 0001213900-26-111794 001-43503 261479689 34 254075 1 1
2026-10-22 4 xslF345X06/ownership.xml 0001213900-26-111795 6107
2026-10-16 3 xslF345X06/ownership.xml 0001213900-26-110379 5159
2026-10-16 SCHEDULE 13G xslSCHEDULE_13G_X02/primary_doc.xml 0001213900-26-110378 005-95962 261467129 34 16105
2026-10-16 SCHEDULE 13G xslSCHEDULE_13G_X02/primary_doc.xml 0000820434-26-000008 005-95962 261465417 34 6999
2026-10-15 SCHEDULE 13G xslSCHEDULE_13G_X02/primary_doc.xml 0000935836-26-000533 005-95962 261462873 34 6886
2026-10-14 SCHEDULE 13D xslSCHEDULE_13D_X02/primary_doc.xml 0001213900-26-109425 005-95962 261460030 34 19177
2026-10-13 S-8 REGISTRATION STATEMENT 0001213900-26-109109 333-299450 261459540 33 340360 1 1
2026-10-13 4 OWNERSHIP DOCUMENT 0001213900-26-109160 15298
2026-10-13 4 xslF345X06/ownership.xml 0001213900-26-109159 11506
2026-10-13 4 xslF345X06/ownership.xml 0001213900-26-109158 7343
2026-10-13 4 xslF345X06/ownership.xml 0001213900-26-109157 5753
2026-10-13 4 xslF345X06/ownership.xml 0001213900-26-109156 11267
2026-10-13 4 xslF345X06/ownership.xml 0001213900-26-109155 8881
2026-10-13 4 xslF345X06/ownership.xml 0001213900-26-109154 11092
2026-10-13 3 xslF345X06/ownership.xml 0001213900-26-109153 8681
2026-10-13 8-K CURRENT REPORT 5.03,9.01 0001213900-26-109024 001-43503 261456928 34 441197 1 1
2026-10-09 424B4 PROSPECTUS 0001213900-26-108587 333-299024 261453816 33 24600305
2026-10-08 EFFECT xslEFFECTX01/primary_doc.xml ,, 9999999995-26-003189 333-299024 261451066 33 1804
2026-10-08 4 xslF345X06/ownership.xml 0001213900-26-108190 5662
2026-10-08 4 xslF345X06/ownership.xml 0001213900-26-108189 5779
2026-10-08 4 xslF345X06/ownership.xml 0001213900-26-108188 5798
2026-10-08 S-1MEF REGISTRATION STATEMENT 0001213900-26-108143 333-299378 261450828 33 207324 1 1
2026-10-08 3 xslF345X06/ownership.xml 0001213900-26-108141 4623
2026-10-08 3 xslF345X06/ownership.xml 0001213900-26-108140 14889
2026-10-08 3 xslF345X06/ownership.xml 0001213900-26-108139 9946
2026-10-08 3 xslF345X06/ownership.xml 0001213900-26-108136 12842
2026-10-08 3 xslF345X06/ownership.xml 0001213900-26-108135 16195
2026-10-08 3 xslF345X06/ownership.xml 0001213900-26-108134 14207
2026-10-08 3 xslF345X06/ownership.xml 0001213900-26-108133 11511
2026-10-08 3 xslF345X06/ownership.xml 0001213900-26-108132 13959
2026-10-08 CERT RTSN_8A_Cert_0002002988.pdf 0001354457-26-000966 001-43503 261450112 34 180717
2026-10-08 8-A12B FOR REGISTRATION OF CERTAIN CLASSES 0001213900-26-107730 001-43503 261448337 34 17917
2026-10-07 S-1/A REGISTRATION STATEMENT 0001213900-26-107572 333-299024 261447087 33 379475 1 1
2026-10-05 S-1/A AMENDMENT NO. 1 TO FORM S-1 0001213900-26-106636 333-299024 261438778 33 25986233 1 1
2026-09-18 S-1 REGISTRATION STATEMENT 0001213900-26-101499 333-299024 261391751 33 31559589 1 1
2026-08-14 DRS/A filename1.htm 0001213900-26-090287 377-09081 261283719 33 28960941
2026-06-16 DRS/A filename1.htm 0001213900-26-069228 377-09081 261094471 33 17354450
2026-05-01 DRS/A filename1.htm 0001213900-26-050520 377-09081 26928163 33 17738131
2026-02-17 DRS filename1.htm 0001213900-26-017320 377-09081 26641910 33 15833720
2025-05-06 D xslFormDX01/primary_doc.xml 06b 0002002988-25-000002 021-545343 25916627 33 9626
2024-05-15 D/A xslFormDX01/primary_doc.xml 06b 0002002988-24-000001 021-498860 24951833 33 12275
2023-12-05 D xslFormDX01/primary_doc.xml 06b 0002002988-23-000002 021-498860 231467285 33 12146

Latest XBRL company facts

One latest value per concept from companyfacts (77 concepts). Full history stays in the JSON.

TaxonomyTagLabelUnitValueStartEndFYFPFormFiledAccn
dei EntityCommonStockSharesOutstanding Entity Common Stock, Shares Outstanding shares 8.89M 2026-11-16 2026 Q3 10-Q 2026-11-18 0001104659-26-129357
ffd NetFeeAmt NetFeeAmt USD 1,226.43 2026-10-13 S-8 2026-10-13 0001213900-26-109109
ffd TtlFeeAmt TtlFeeAmt USD 1,226.43 2026-10-13 S-8 2026-10-13 0001213900-26-109109
ffd TtlOfferingAmt TtlOfferingAmt USD 14.10M 2026-10-13 S-8 2026-10-13 0001213900-26-109109
ffd TtlOffsetAmt TtlOffsetAmt USD 0 2026-10-13 S-8 2026-10-13 0001213900-26-109109
ffd TtlPrevslyPdAmt TtlPrevslyPdAmt USD 0 2026-10-08 S-1MEF 2026-10-08 0001213900-26-108143
us-gaap AccountsPayableCurrent Accounts Payable, Current USD 3.89M 2026-09-30 2026 Q3 10-Q 2026-11-18 0001104659-26-129357
us-gaap AccruedLiabilitiesCurrent Accrued Liabilities, Current USD 2.77M 2026-09-30 2026 Q3 10-Q 2026-11-18 0001104659-26-129357
us-gaap AdditionalPaidInCapital Additional Paid in Capital USD 1.09M 2026-09-30 2026 Q3 10-Q 2026-11-18 0001104659-26-129357
us-gaap AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD 175,391 2026-07-01 2026-09-30 2026 Q3 10-Q 2026-11-18 0001104659-26-129357
us-gaap AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount shares 5.16M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-18 0001104659-26-129357
us-gaap Assets Assets USD 14.15M 2026-09-30 2026 Q3 10-Q 2026-11-18 0001104659-26-129357
us-gaap AssetsCurrent Assets, Current USD 14.15M 2026-09-30 2026 Q3 10-Q 2026-11-18 0001104659-26-129357
us-gaap CashAndCashEquivalentsAtCarryingValue Cash and Cash Equivalents, at Carrying Value USD 9.19M 2026-09-30 2026 Q3 10-Q 2026-11-18 0001104659-26-129357
us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents USD 9.19M 2026-09-30 2026 Q3 10-Q 2026-11-18 0001104659-26-129357
us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect USD -9.71M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-18 0001104659-26-129357
us-gaap ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Class of Warrant or Right, Exercise Price of Warrants or Rights USD/shares 7.21 2026-09-30 2026 Q3 10-Q 2026-11-18 0001104659-26-129357
us-gaap ClassOfWarrantOrRightOutstanding Class of Warrant or Right, Outstanding shares 349,930 2026-09-30 2026 Q3 10-Q 2026-11-18 0001104659-26-129357
us-gaap CommonStockParOrStatedValuePerShare Common Stock, Par or Stated Value Per Share USD/shares 0 2026-09-30 2026 Q3 10-Q 2026-11-18 0001104659-26-129357
us-gaap CommonStockSharesAuthorized Common Stock, Shares Authorized shares 36.00M 2026-09-30 2026 Q3 10-Q 2026-11-18 0001104659-26-129357
us-gaap CommonStockSharesIssued Common Stock, Shares, Issued shares 807,928 2026-09-30 2026 Q3 10-Q 2026-11-18 0001104659-26-129357
us-gaap CommonStockSharesOutstanding Common Stock, Shares, Outstanding shares 807,928 2026-09-30 2026 Q3 10-Q 2026-11-18 0001104659-26-129357
us-gaap CommonStockValue Common Stock, Value, Issued USD 81 2026-09-30 2026 Q3 10-Q 2026-11-18 0001104659-26-129357
us-gaap DeferredOfferingCosts Deferred Offering Costs USD 2.49M 2026-09-30 2026 Q3 10-Q 2026-11-18 0001104659-26-129357
us-gaap EarningsPerShareBasic Earnings Per Share, Basic USD/shares -16.65 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-18 0001104659-26-129357
us-gaap EarningsPerShareDiluted Earnings Per Share, Diluted USD/shares -16.65 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-18 0001104659-26-129357
us-gaap ForeignCurrencyTransactionGainLossBeforeTax Foreign Currency Transaction Gain (Loss), before Tax USD -856 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-18 0001104659-26-129357
us-gaap GeneralAndAdministrativeExpense General and Administrative Expense USD 2.57M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-18 0001104659-26-129357
us-gaap IncreaseDecreaseInAccountsPayableTrade Increase (Decrease) in Accounts Payable, Trade USD 3.07M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-18 0001104659-26-129357
us-gaap IncreaseDecreaseInAccruedLiabilities Increase (Decrease) in Accrued Liabilities USD 672,045 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-18 0001104659-26-129357
us-gaap IncreaseDecreaseInDueToRelatedPartiesCurrent Increase (Decrease) in Due to Related Parties, Current USD 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-18 0001104659-26-129357
us-gaap IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Increase (Decrease) in Prepaid Expense and Other Assets USD 134,444 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-18 0001104659-26-129357
us-gaap InvestmentIncomeInterest Investment Income, Interest USD 351,457 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-18 0001104659-26-129357
us-gaap Liabilities Liabilities USD 6.66M 2026-09-30 2026 Q3 10-Q 2026-11-18 0001104659-26-129357
us-gaap LiabilitiesAndStockholdersEquity Liabilities and Equity USD 14.15M 2026-09-30 2026 Q3 10-Q 2026-11-18 0001104659-26-129357
us-gaap LiabilitiesCurrent Liabilities, Current USD 6.66M 2026-09-30 2026 Q3 10-Q 2026-11-18 0001104659-26-129357
us-gaap NetCashProvidedByUsedInFinancingActivities Net Cash Provided by (Used in) Financing Activities USD -294,607 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-18 0001104659-26-129357
us-gaap NetCashProvidedByUsedInOperatingActivities Net Cash Provided by (Used in) Operating Activities USD -9.42M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-18 0001104659-26-129357
us-gaap NetIncomeLoss Net Income (Loss) Attributable to Parent USD -13.44M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-18 0001104659-26-129357
us-gaap NonoperatingIncomeExpense Nonoperating Income (Expense) USD 350,601 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-18 0001104659-26-129357
us-gaap NumberOfOperatingSegments Number of Operating Segments segment 1 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-18 0001104659-26-129357
us-gaap NumberOfReportableSegments Number of Reportable Segments segment 1 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-18 0001104659-26-129357
us-gaap OperatingExpenses Operating Expenses USD 13.79M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-18 0001104659-26-129357
us-gaap OperatingIncomeLoss Operating Income (Loss) USD -13.79M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-18 0001104659-26-129357
us-gaap PaymentsForRoyalties Payments for Royalties USD 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-18 0001104659-26-129357
us-gaap PaymentsOfStockIssuanceCosts Payments of Stock Issuance Costs USD 297,543 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-18 0001104659-26-129357
us-gaap PrepaidExpenseAndOtherAssetsCurrent Prepaid Expense and Other Assets, Current USD 2.47M 2026-09-30 2026 Q3 10-Q 2026-11-18 0001104659-26-129357
us-gaap ProceedsFromStockOptionsExercised Proceeds from Stock Options Exercised USD 3,961 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-18 0001104659-26-129357
us-gaap ProfitLoss Net Income (Loss), Including Portion Attributable to Noncontrolling Interest USD -13.44M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-18 0001104659-26-129357
us-gaap ResearchAndDevelopmentExpense Research and Development Expense USD 11.22M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-18 0001104659-26-129357
us-gaap RetainedEarningsAccumulatedDeficit Retained Earnings (Accumulated Deficit) USD -21.76M 2026-09-30 2026 Q3 10-Q 2026-11-18 0001104659-26-129357
us-gaap ShareBasedCompensation Share-based Payment Arrangement, Noncash Expense USD 417,047 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-18 0001104659-26-129357
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate pure 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-18 0001104659-26-129357
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate pure 0 2025-01-01 2025-12-31 2026 Q3 10-Q 2026-11-18 0001104659-26-129357
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum pure 0.603 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-18 0001104659-26-129357
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum pure 0.575 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-18 0001104659-26-129357
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate pure 0 2025-01-01 2025-12-31 2026 Q3 10-Q 2026-11-18 0001104659-26-129357
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum pure 0.044 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-18 0001104659-26-129357
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum pure 0.042 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-18 0001104659-26-129357
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number shares 542,456 2026-09-30 2026 Q3 10-Q 2026-11-18 0001104659-26-129357
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price USD/shares 1.72 2026-09-30 2026 Q3 10-Q 2026-11-18 0001104659-26-129357
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period shares 15,656 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-18 0001104659-26-129357
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price USD/shares 2.43 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-18 0001104659-26-129357
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross shares 402,583 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-18 0001104659-26-129357
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number shares 1.23M 2026-09-30 2026 Q3 10-Q 2026-11-18 0001104659-26-129357
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price USD/shares 2.1 2026-09-30 2026 Q3 10-Q 2026-11-18 0001104659-26-129357
us-gaap ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price USD/shares 1.43 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-18 0001104659-26-129357
us-gaap ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price USD/shares 2.43 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-18 0001104659-26-129357
us-gaap StockholdersEquity Stockholders' Equity Attributable to Parent USD -20.66M 2026-09-30 2026 Q3 10-Q 2026-11-18 0001104659-26-129357
us-gaap StockIssuedDuringPeriodSharesStockOptionsExercised Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period shares 2,774 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-18 0001104659-26-129357
us-gaap StockIssuedDuringPeriodValueStockOptionsExercised Stock Issued During Period, Value, Stock Options Exercised USD 639 2026-07-01 2026-09-30 2026 Q3 10-Q 2026-11-18 0001104659-26-129357
us-gaap TemporaryEquityCarryingAmountAttributableToParent Temporary Equity, Carrying Amount, Attributable to Parent USD 28.15M 2026-09-30 2026 Q3 10-Q 2026-11-18 0001104659-26-129357
us-gaap TemporaryEquitySharesAuthorized Temporary Equity, Shares Authorized shares 23.44M 2026-09-30 2026 Q3 10-Q 2026-11-18 0001104659-26-129357
us-gaap TemporaryEquityStockIssuedDuringPeriodValueNewIssues Temporary Equity, Stock Issued During Period, Value, New Issues USD 2.40M 2025-07-01 2025-09-30 2026 Q3 10-Q 2026-11-18 0001104659-26-129357
us-gaap UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic Undistributed Earnings (Loss) Allocated to Participating Securities, Basic USD 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-18 0001104659-26-129357
us-gaap WeightedAverageNumberOfDilutedSharesOutstanding Weighted Average Number of Shares Outstanding, Diluted shares 807,287 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-18 0001104659-26-129357
us-gaap WeightedAverageNumberOfSharesOutstandingBasic Weighted Average Number of Shares Outstanding, Basic shares 807,287 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-18 0001104659-26-129357

Financialist News Desk

Our desk turns official SEC filings into news. Each story is checked against the original filing. About us → · Editorial standards →